Immunohistochemistry - Global Strategic Business Report

Global Immunohistochemistry Market to Reach $4 Billion by 2030

The global market for Immunohistochemistry estimated at US$2.3 Billion in the year 2022, is projected to reach a revised size of US$4 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2022-2030. Antibodies, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$1.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Equipment segment is readjusted to a revised 6.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $699.7 Million, While China is Forecast to Grow at 6.6% CAGR

The Immunohistochemistry market in the U.S. is estimated at US$699.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$691.6 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Select Competitors (Total 31 Featured) -

• Abcam PLC
• Agilent Technologies, Inc.
• Bio Sb, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• MilliporeSigma
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year